# SARS-CoV-2 and Acetylsalicylic Acid (SARA)

> **NCT05073718** · PHASE3 · COMPLETED · sponsor: **Barcelona Institute for Global Health** · enrollment: 38 (actual)

## Conditions studied

- SARS-CoV2 Infection
- Covid19

## Interventions

- **DRUG:** Low-dose acetylsalicylic acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05073718
- **Lead sponsor:** Barcelona Institute for Global Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-14
- **Primary completion:** 2024-05-23
- **Final completion:** 2024-05-23
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-08-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05073718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05073718, "SARS-CoV-2 and Acetylsalicylic Acid (SARA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05073718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*